Stay updated on Entinostat + Pembrolizumab in Lymphomas Clinical Trial
Sign up to get notified when there's something new on the Entinostat + Pembrolizumab in Lymphomas Clinical Trial page.

Latest updates to the Entinostat + Pembrolizumab in Lymphomas Clinical Trial page
- Check7 days agoChange DetectedA notice appears announcing NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology. It is shown above the study page’s 403 error.SummaryDifference1%

- Check14 days agoChange DetectedThe footer revision number changed from v3.7.1 to v3.7.2 while the page continues to display a 403 error.SummaryDifference0.2%

- Check21 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the previous study content with a generic error page. This indicates that access to the NCT03179930 study record is blocked, with the error text visible on the page.SummaryDifference18%

- Check64 days agoChange DetectedThe page's revision label in the footer updated from v3.6.5 to v3.6.6, signaling a newer build of the ClinicalTrials.gov page.SummaryDifference0.1%

- Check85 days agoChange DetectedThe bottom of the page shows a revision stamp updated from v3.6.4 to v3.6.5, indicating a minor template or deployment update. This appears to be a routine system update rather than a change to study information.SummaryDifference0.1%

Stay in the know with updates to Entinostat + Pembrolizumab in Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Entinostat + Pembrolizumab in Lymphomas Clinical Trial page.